Compare Monster Beverage Corp (MNST) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs BIO-TECHNE Corp — how do they compare? Monster Beverage Corp trades at $43.6 (market cap $84.00B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Monster Beverage Corp is far larger — about 7.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and BIO-TECHNE Corp for 63 Days on average.
| MNST | TECH | |
|---|---|---|
Market Cap | $84.00B | $11.37B |
Volume | 8,371,981 | 3,153,511 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $72.61 |
52-Week Low | $33.16 | $43.31 |
Typical Hold Time | 72 Days | 63 Days |
Enterprise Value | $82.30B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.65, up 0.92% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net income margin of 23.08%. Recent news highlights its debt-free balance sheet and international expansion, particularly a 35% surge in overseas sales.
The outlook is mixed: strong fundamentals and analyst consensus support upside to a $98.22 price target, but the stock faces headwinds from rich valuations (P/E 39.7) and technical bearishness. Key risks include inflation pressures and regulatory challenges, such as India's label ban. Institutional sentiment leans bullish, with 52% of analysts rating it Buy.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
